Trial Profile
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Disease-modifying antirheumatics; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 12 Nov 2012 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria' has been met.
- 09 Jun 2012 Main study results presented at the 13th Annual Congress of the European League Against Rheumatism.